Hemcheck has today completed the transaction with Bio Vitos as Bio Vitos has subscribed for all the shares according to the agreement and paid in the agreed funds so that the decided new share issue can be carried out.

- It is very positive that we have completed the transaction with Bio Vitos and that the company can now take the next step in line with the plan that has been drawn up. The IP rights regarding iron succinate have large potential and now the work begins to realize this potential. Shortly we will call for an extra general meeting to elect new board members and change the name of the company, says Joen Averstad, acting CEO of Hemcheck.

For further information contact:
Hemcheck Sweden AB (publ)
Joen Averstad, acting CEO
Tel: +46 76 108 8191
Email: joen.averstad@hemcheck.com

About Hemcheck

Hemcheck Sweden AB, founded in 2010, produces and commercializes a patented CE-marked concept for point of care hemolysis detection. The concept consists of disposable tests as well as readers that can very quickly, directly upon sampling, identify hemolysed blood samples in vacuum tubes and blood gas syringes. Hemolysis, ruptured red blood cells, is the most common reason globally why blood samples cannot be analyzed accurately and is also a biomarker for acute medical conditions. Hemcheck’s goal is to contribute to improved healthcare by offering user-friendly solutions for the detection of hemolysed blood samples in direct connection with blood sampling near the patient. By doing so, Hemcheck can contribute to increased patient safety, more efficient processes and lower costs. The company is listed on the Nasdaq First North Growth Market.

FNCA Sweden AB is the Certified Adviser to the company.